HealthcareA pharma & life sciences business typically supports 2.6x to 3.1x EBITDA of debt, depending on cash flow stability and existing commitments. Estimate your borrowing capacity in SGD below.
Based on middle-market lending data for Singapore. Actual terms vary based on company-specific factors.
Singapore lenders typically structure pharma & life sciences facilities with comprehensive covenant packages aligned with international standards. Standard covenant packages include maximum Debt/EBITDA of 3x, minimum DSCR of 1.
Complete the form below to get your personalized borrowing capacity analysis in SGD
Singaporean pharmaceutical and life sciences companies access sophisticated financing markets as Asia's premier biomedical hub regulated by the Health Sciences Authority (HSA). Singapore pharma benefits from strong regulatory reputation, regional headquarters positioning, and deep capital markets access.
Singapore pharma financing involves DBS, OCBC, UOB, international banks, healthcare-focused lenders, and venture capital understanding HSA requirements. Drug registration and regional commercial strategies affect positioning. The sophisticated market provides varied structures for different company stages.
Singapore pharma companies typically achieve leverage of 2.0-3.0x EBITDA with revenue quality, regulatory approvals, and organizational strength influencing terms. HSA approval provides rigorous regulatory credential. Regional expansion from Singapore base creates financing needs. Manufacturing and R&D capabilities support assessment.
The Singapore lending environment evaluates revenue quality, regulatory standing, commercial execution, and competitive positioning. Regional drug registration and market access matter. Biomedical Sciences Initiative supports sector development. The hub status attracts substantial pharma financing capacity.
Singapore pharma sector evolution drives financing needs. Cell and gene therapy development, regional expansion, and manufacturing investment create opportunities. Government biomedical initiatives support sector growth. These dynamics shape debt capacity for Singapore pharmaceutical companies.
Singapore offers one of Asia's most sophisticated SME financing ecosystems. Local banks (DBS, OCBC, UOB) dominate the market, while Enterprise Singapore provides extensive government support through various financing schemes. The city-state's strong legal framework and business-friendly environment attract competitive lending terms. Primary lenders for pharma & life sciences businesses in Singapore include Local Banks (DBS, OCBC, UOB), Foreign Banks, Finance Companies, Alternative Lenders, Government-Linked Entities. The market is characterized by sophisticated with strong government support and competitive rates, with typical senior debt rates of 4-8% for quality credits. Lender appetite for pharma & life sciences credits is strong given the sector's medium asset intensity and low cyclicality.
Singapore lenders typically structure pharma & life sciences facilities with comprehensive covenant packages aligned with international standards. Standard covenant packages include maximum Debt/EBITDA of 3x, minimum DSCR of 1.25x, and fixed charge coverage requirements. Standard covenants typically provide adequate headroom for well-managed businesses. Pharma & Life Sciences companies should maintain covenant cushion of 15-20% to accommodate business fluctuations.
MAS (Monetary Authority of Singapore) provides robust banking regulation. Enterprise Singapore schemes offer government risk-sharing up to 90%. Interest is tax-deductible against corporate tax. For pharma & life sciences businesses, specific considerations include collateral documentation requirements and compliance with local lending regulations. Government support through Enterprise Financing Scheme (EFS) may provide credit enhancement or favorable terms for qualifying businesses.
Use our free valuation calculator to estimate your pharma & life sciences business worth in SGD.
Tell us what you're working on. We'll tell you how we'd approach it. We respond within 24 hours.
Perspectives on corporate finance, fundraising, and M&A, from the Alehar team.
United States
United Kingdom
United Arab Emirates
Saudi Arabia
India